NCT00063089View on ClinicalTrials.gov

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Staphylococcal Infections
Interventions
DRUG

S. aureus Immune Globulin Intravenous (Human) 5%

Sponsors
All Listed Sponsors
lead

Nabi Biopharmaceuticals

INDUSTRY

NCT00063089 - Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever | Biotech Hunter | Biotech Hunter